Activating this mechanism by enhancing resident FGF19, via pharmacological intervention with FGF19 or an appropriate analogue, may supply a powerful and novel therapeutic approach to treating PBC-AIH OS patients. The gene discussed is FGF19; the disease is primary biliary cholangitis.